| Code | 7816D | ||||||||||
| MA number | 44/0169/21-S | ||||||||||
| Product Form: | cps dur 30x50 mg (fľ.HDPE) | ||||||||||
| MA Status: | R - Valid Marketing Authorisation | ||||||||||
| Type of procedure: | Decentralised | ||||||||||
| Therapeutic Class: | 44 - CYTOSTATICA | ||||||||||
| ATC: |
|
||||||||||
| Shelf life: | 24 | ||||||||||
| Route of admin.: | Oral use |
| Prescription Status: | Medicinal product subject to restricted medical prescription. |
| Legal basis: | Article 10(1) generic application |
| MA issued: | 18.06.2021 |
| Validity: | 18.06.2026 |
| PIL: |
PIL_Sunitinib Krka 12,5 mg 25 mg 50 mg cps dur_jún 21.pdf
|
| SPC: |
SPC_Sunitinib Krka 12,5 mg 25 mg 50 mg cps dur_jún 21.pdf
|
| Safety feature | Yes |
| Data update: | 17.01.2022 |
